基于组学技术的中医药干预腹泻型肠易激综合征机制研究进展OA

Irritable bowel syndrome with diarrhea(IBS-D),as a prototypical disorder involving the microbiota-gut-brain axis,remains poorly understood in terms of its pathogenesis,posing ongoing challenges for clinical diagnosis.Omics technologies,leveraging their high-throughput detection and systematic analysis advantages,has emerged as a critical tool for deciphering the complex mechanisms underlying traditional Chinese medicine(TCM)treatment of IBS-D.This systematic review summarizes the research progress of transcriptomics,proteomics,metabolomics,microbiomics,and multi-omics integration techniques in TCM interventions for IBS-D.In single-omics studies,transcriptomics using techniques like RNA-seq,reveals the regulatory mechanisms of TCM on IBS-related signaling pathways.Proteomics,leveraging quantitative technologies such as 2D-difference gel electrophoresis and tandem mass tag,identifies differentially expressed proteins and elucidates the action targets of TCM in treating IBS-D.Metabolomics,employing methods like UPLC-Q-TOF-MS and LC-MS/MS,discovers metabolic pathways regulated by TCM to improve metabolic disturbances in IBS-D.Microbiomics,based on 16S rRNA sequencing,confirms that TCM can reshape the gut microbiota structure and restore the intestinal microecological balance,thereby improving IBS-D.Multi-omics integration further overcomes the limitations of single-omics approaches by synthesizing information from transcriptomics,proteomics,metabolomics,and microbiomics,enabling a more comprehensive and systematic elucidation of the complex mechanisms underlying TCM treatment for IBS-D.In the future,research related to IBS-D should be advanced from three aspects:stratified clinical research based on TCM syndrome types,multi-omics integration verification mechanisms,and emerging omics to explore new mechanisms,providing more innovative ideas for the precise diagnosis and treatment of this disease.